View Older Stories View More Recent Stories

Oct 6, 2022 08:30AM DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial
Sep 26, 2022 08:33AM DURECT Corp (DRRX), Innocoll Announce U.S. launch of POSIMIR
Sep 26, 2022 08:30AM Innocoll and DURECT Announce U.S. launch of POSIMIR®
Sep 6, 2022 08:00AM DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
Aug 4, 2022 04:05PM DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs
Jul 27, 2022 04:15PM DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4
Jul 5, 2022 08:30AM DURECT Corp (DRRX) Appoints Timothy M. Papp as Chief Financial Officer
Jul 5, 2022 08:30AM DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer
May 18, 2022 01:53PM DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
May 4, 2022 04:05PM DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs
Apr 27, 2022 04:15PM DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4
Mar 23, 2022 04:15PM DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit
Mar 9, 2022 04:30PM DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
Mar 7, 2022 04:05PM DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs
Mar 1, 2022 08:30AM DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis
Feb 28, 2022 04:30PM DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7
Jan 6, 2022 04:05PM DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference
Dec 22, 2021 07:31AM DURECT Corp (DRRX) and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR
Dec 22, 2021 07:30AM DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
Dec 14, 2021 09:00AM DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia
Nov 29, 2021 09:00AM DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit
Nov 12, 2021 09:00AM Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.
Nov 10, 2021 09:00AM DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis
Nov 8, 2021 09:00AM DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021
Nov 2, 2021 04:05PM DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs
Oct 26, 2021 09:00AM DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2
Oct 7, 2021 09:00AM DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference
Sep 23, 2021 09:00AM DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021
Sep 15, 2021 09:00AM DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit
Sep 7, 2021 09:00AM DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference
Jul 29, 2021 04:05PM DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs
Jul 22, 2021 08:30AM DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29
Jul 14, 2021 04:30PM DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit
Jun 23, 2021 09:06AM DURECT Corp (DRRX) Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at EASL
Jun 23, 2021 09:00AM DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)
Jun 9, 2021 09:00AM DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
May 4, 2021 04:05PM DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs
Apr 27, 2021 08:30AM DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4
Mar 9, 2021 09:06AM DURECT Corp (DRRX) Reports Publication of DUR-928's Mechanism of Action
Mar 9, 2021 09:00AM DURECT Corporation Announces Publication of DUR-928's Mechanism of Action
Mar 4, 2021 04:05PM DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs
Mar 3, 2021 06:02PM DURECT Corporation to Participate in Three Investor Conferences in March 2021
Feb 25, 2021 04:05PM DURECT Corporation to Announce 2020 Financial Results and Provide Business Update on March 4
Feb 2, 2021 08:03AM DURECT Corp (DRRX) Announces U.S. FDA Approval of POSIMIR For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
Feb 2, 2021 08:01AM DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
Jan 25, 2021 08:33AM DURECT Corp (DRRX) Reports First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis
Jan 25, 2021 08:30AM DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis
Jan 5, 2021 08:34AM DURECT Corp (DRRX) Announces Gail J. Maderis and Mohammad Azab to Board
Jan 5, 2021 08:30AM DURECT Corporation Appoints Two New Board Members
Jan 4, 2021 08:30AM DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million
View More Recent Stories View Older Stories